Literature DB >> 27882196

Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.

Donglu Zhang1, Thomas H Pillow1, Yong Ma1, Josefa Dela Cruz-Chuh1, Katherine R Kozak1, Jack D Sadowsky1, Gail D Lewis Phillips1, Jun Guo1, Martine Darwish1, Peter Fan1, Jingtian Chen2, Changrong He2, Tao Wang2, Hui Yao2, Zijin Xu2, Jinhua Chen2, John Wai2, Zhonghua Pei1, Cornelis E C A Hop1, S Cyrus Khojasteh1, Peter S Dragovich1.   

Abstract

Disulfide bonds could be valuable linkers for a variety of therapeutic applications requiring tunable cleavage between two parts of a molecule (e.g., antibody-drug conjugates). The in vitro linker immolation of β-mercaptoethyl-carbamate disulfides and DNA alkylation properties of associated payloads were investigated to understand the determinant of cell killing potency of anti-CD22 linked pyrrolobenzodiazepine (PBD-dimer) conjugates. Efficient immolation and release of a PBD-dimer with strong DNA alkylation properties were observed following disulfide cleavage of methyl- and cyclobutyl-substituted disulfide linkers. However, the analogous cyclopropyl-containing linker did not immolate, and the associated thiol-containing product was a poor DNA alkylator. As predicted from these in vitro assessments, the related anti-CD22 ADCs showed different target-dependent cell killing activities in WSU-DLCL2 and BJAB cell lines. These results demonstrate how the in vitro immolation models can be used to help design efficacious ADCs.

Entities:  

Keywords:  Antibody−drug conjugate; cancer; disulfide linker; linker immolation; pyrrolobenzodiazepine

Year:  2016        PMID: 27882196      PMCID: PMC5108036          DOI: 10.1021/acsmedchemlett.6b00233

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

1.  The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.

Authors:  Khondaker M Rahman; Andrew S Thompson; Colin H James; Mathangi Narayanaswamy; David E Thurston
Journal:  J Am Chem Soc       Date:  2009-09-30       Impact factor: 15.419

Review 2.  Disulfide-containing parenteral delivery systems and their redox-biological fate.

Authors:  Lorine Brülisauer; Marc A Gauthier; Jean-Christophe Leroux
Journal:  J Control Release       Date:  2014-06-18       Impact factor: 9.776

Review 3.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

Review 4.  ADME of antibody-maytansinoid conjugates.

Authors:  Hans K Erickson; John M Lambert
Journal:  AAPS J       Date:  2012-08-09       Impact factor: 4.009

Review 5.  The development of pyrrolobenzodiazepines as antitumour agents.

Authors:  John A Hartley
Journal:  Expert Opin Investig Drugs       Date:  2011-04-04       Impact factor: 6.206

6.  Effect of hairpin loop structure on reactivity, sequence preference and adduct orientation of a DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agent.

Authors:  David E Thurston; Higia Vassoler; Paul J M Jackson; Colin H James; Khondaker M Rahman
Journal:  Org Biomol Chem       Date:  2015-04-07       Impact factor: 3.876

7.  Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Jagath R Junutula; Kelly M Flagella; Richard A Graham; Kathryn L Parsons; Edward Ha; Helga Raab; Sunil Bhakta; Trung Nguyen; Debra L Dugger; Guangmin Li; Elaine Mai; Gail D Lewis Phillips; Hajime Hiraragi; Reina N Fuji; Jay Tibbitts; Richard Vandlen; Susan D Spencer; Richard H Scheller; Paul Polakis; Mark X Sliwkowski
Journal:  Clin Cancer Res       Date:  2010-08-30       Impact factor: 12.531

8.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

9.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Authors:  May S Kung Sutherland; Roland B Walter; Scott C Jeffrey; Patrick J Burke; Changpu Yu; Heather Kostner; Ivan Stone; Maureen C Ryan; Django Sussman; Robert P Lyon; Weiping Zeng; Kimberly H Harrington; Kerry Klussman; Lori Westendorf; David Meyer; Irwin D Bernstein; Peter D Senter; Dennis R Benjamin; Jonathan G Drachman; Julie A McEarchern
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

10.  Pyrrol[1,4]benzodiazepine antibiotics. Proposed structures and characteristics of the in vitro deoxyribonucleic acid adducts of anthramycin, tomaymycin, sibiromycin, and neothramycins A and B.

Authors:  R L Petrusek; G L Anderson; T F Garner; Q L Fannin; D J Kaplan; S G Zimmer; L H Hurley
Journal:  Biochemistry       Date:  1981-03-03       Impact factor: 3.162

View more
  8 in total

1.  DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Authors:  Joan Tymon-Rosario; Elena Bonazzoli; Stefania Bellone; Aranzazu Manzano; Silvia Pelligra; Adele Guglielmi; Barbara Gnutti; Nupur Nagarkatti; Burak Zeybek; Paola Manara; Luca Zammataro; Justin Harold; Dennis Mauricio; Natalia Buza; Pei Hui; Gary Altwerger; Gulden Menderes; Elena Ratner; Mitchell Clark; Vaagn Andikyan; Gloria S Huang; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2021-08-25       Impact factor: 5.304

Review 2.  Novel antibody-drug conjugates: current and future roles in gynecologic oncology.

Authors:  Joan Tymon-Rosario; Burak Zeybek; Alessandro D Santin
Journal:  Curr Opin Obstet Gynecol       Date:  2021-02-01       Impact factor: 1.927

Review 3.  Disulfide based prodrugs for cancer therapy.

Authors:  Qiang Wang; Jiankun Guan; Jiangling Wan; Zifu Li
Journal:  RSC Adv       Date:  2020-06-25       Impact factor: 4.036

Review 4.  The Analysis of Key Factors Related to ADCs Structural Design.

Authors:  Haichao Tang; Yan Liu; Zhaojin Yu; Mingli Sun; Lu Lin; Wensi Liu; Qiang Han; Minjie Wei; Ying Jin
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

5.  Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells.

Authors:  Alla Pryyma; Kaveh Matinkhoo; Yong Jia Bu; Helen Merkens; Zhengxing Zhang; Francois Bénard; David M Perrin
Journal:  RSC Chem Biol       Date:  2021-10-07

6.  A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates.

Authors:  Penghui Zhang; Di Gao; Keli An; Qi Shen; Chen Wang; Yuchao Zhang; Xiaoshu Pan; Xigao Chen; Yifan Lyv; Cheng Cui; Tingxizi Liang; Xiaoman Duan; Jie Liu; Tielin Yang; Xiaoxiao Hu; Jun-Jie Zhu; Feng Xu; Weihong Tan
Journal:  Nat Chem       Date:  2020-03-09       Impact factor: 24.427

7.  Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency.

Authors:  Dian Su; Donglu Zhang
Journal:  Front Pharmacol       Date:  2021-06-23       Impact factor: 5.810

Review 8.  Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.

Authors:  Penelope M Drake; David Rabuka
Journal:  BioDrugs       Date:  2017-12       Impact factor: 5.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.